Sanofi, a pharmaceutical company with sites in Ghent and Diegem, is set to cut 99 jobs as part of a global restructuring effort. The company confirmed the information, stating that 67 jobs are targeted in Ghent and 32 at the head office in Diegem. This restructuring is necessary for Sanofi to modernize its organization and become a global player in immunology.
The company’s focus is on developing new vaccines and drugs in immunology that can have a significant impact on patient care. Sanofi has twelve new medicines and vaccines in clinical development that show promise for treating immune-related diseases. As a result, some early-stage research activities in Ghent will be discontinued. However, Sanofi is exploring all possible solutions for employees affected by the job cuts.
In addition to pharmaceutical developments, Sanofi is also investing heavily in renewable energy technologies. The demand for solar and photovoltaic technologies is expected to continue growing as countries strive to meet their sustainability goals in 2024. These technologies play a crucial role in the transition to renewable energy sources and reducing carbon emissions.
For more information on Sanofi’s pharmaceutical developments, renewable energy technologies, and job restructuring efforts, please visit the company’s official website or contact their representatives directly.
